Quarterly ResultMay 8, 2026, 06:11 AM
QIAGEN Q1 Net Sales $492M, Adj. EPS $0.54; FY26 Outlook Reconfirmed
AI Summary
QIAGEN N.V. reported Q1 2026 results in line with its preliminary announcement, with net sales rising 2% to $492 million (down 1% CER) and adjusted diluted EPS of $0.54, meeting the outlook. Sales trends were mixed, showing solid growth in Sample technologies, QIAcuity, and QIAGEN Digital Insights, but offset by a 5% CER decline in QuantiFERON sales due to significantly lower immigration testing demand and cautious U.S. Life Sciences customer spending. The company reconfirmed its updated full-year 2026 outlook for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER, anticipating stronger growth in the second half.
Key Highlights
- Q1 2026 net sales rose 2% to $492 million, but declined 1% at constant exchange rates (CER).
- Q1 2026 adjusted diluted EPS was $0.54, in line with the company's outlook.
- Sample technologies sales grew 9% CER to $170 million, or 3% CER excluding Parse acquisition.
- QuantiFERON sales declined 5% CER, mainly due to significantly lower immigration testing demand.
- Full-year 2026 net sales outlook reconfirmed at about 1-2% CER growth.
- Full-year 2026 adjusted diluted EPS outlook reconfirmed at least $2.43 CER.
- Net cash provided by operating activities was $101 million, down 28% from Q1 2025.
- Completed a $500 million synthetic share repurchase in Q1 2026, reducing shares by 5%.